Celcuity LLC

Yahoo Finance • 4 days ago

Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinica... Full story

Yahoo Finance • 26 days ago

Abivax’s 580% surge hands biotech hedge funds a rare 2025 win

[Scientist taking a sample out of a petri dish using a pipette] DNY59/E+ via Getty Images Hedge funds specializing in biotech finally caught a break this summer, courtesy of a little-watched French drug developer, The Wall Street Journal... Full story

Yahoo Finance • 28 days ago

3 Growth Companies With High Insider Ownership And 58% Earnings Growth

As the U.S. stock market continues its upward trajectory, with major indices like the S&P 500 and Dow Jones Industrial Average closing at record highs, investors are increasingly focused on growth opportunities amid economic data releases... Full story

Yahoo Finance • 29 days ago

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program

MINNEAPOLIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration (“FDA”) ag... Full story

Yahoo Finance • last month

Add Up The Pieces: IWV Could Be Worth $403

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • last month

Catalyst Watch: Eyes on Jackson Hole, Walmart report, Google event, and Foot Locker-Dick's vote

[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MO... Full story

Yahoo Finance • last month

Needham lowers Celcuity stock price target to $70 on dilution concerns

Investing.com - Needham lowered its price target on Celcuity Inc (NASDAQ:CELC) to $70.00 from $74.00 on Friday, while maintaining a Buy rating on the stock. Currently trading at $51.89, the $2.1 billion market cap company has seen impressi... Full story

Yahoo Finance • last month

Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Reported statistically significant and clinically meaningful improvement in both primary endpoints from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trialHazard ratios and improvements in median progression-free survival (“PFS”) a... Full story

Yahoo Finance • 2 months ago

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for t... Full story

Yahoo Finance • 2 months ago

Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants

MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten... Full story

Yahoo Finance • 2 months ago

Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on Monday. Celcuity soared by 167 percent on Monday to close at $36.79 apiece as investors cheered positive results in... Full story

Yahoo Finance • 2 months ago

Celcuity announces $225M combined offerings; shares down

* Celcuity (NASDAQ:CELC [https://seekingalpha.com/symbol/CELC]) plans to raise $225M through public offerings of convertible senior notes and common stock. * The company will offer $150M in convertible senior notes due 2031. * A conc... Full story

Yahoo Finance • 2 months ago

Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced proposed underwritten public off... Full story

Yahoo Finance • 2 months ago

AMD and Tesla Lead Monday's Market Cap Stock Movers

Monday’s market has seen notable fluctuations, with stocks like Adv Micro Device (NASDAQ:AMD) and Tesla Motors (NASDAQ:TSLA) experiencing gains, while others such as Super Micro Compu (NASDAQ:SMCI) and Perkinelmer (NYSE:RVTY) (PKI)... Full story

Yahoo Finance • 2 months ago

Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More

NHAC NGUYEN / AFP via Getty Images was the best-performing stock in the Dow Jones Industrial Average on Monday, July 28, 2025 Key Takeaways U.S. equities gained at midday on news of a new trade deal between the U.S. and the European Unio... Full story

Yahoo Finance • 2 months ago

AMD and ServiceNow Highlight Monday's Market Cap Stock Movers

Monday’s market has seen notable movements among a range of stocks, with significant activity in both the mega-cap and large-cap categories. While stocks such as Adv Micro Device (NASDAQ:AMD) and ServiceNow Inc (NYSE:NOW) have experience... Full story

Yahoo Finance • 2 months ago

Celcuity to announce phase 3 VIKTORIA-1 trial results on Monday

MINNEAPOLIS - Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company with a market capitalization of $527 million, will hold a conference call and webcast on Monday, July 28, 2025, at 8:00 AM ET to disclose topline results fro... Full story

Yahoo Finance • 2 months ago

Celcuity stock jumps ahead of pivotal breast cancer trial results

Investing.com -- Celcuity Inc. (NASDAQ:CELC) stock rose 5.2% after the clinical-stage biotechnology company announced it will hold a conference call on Monday, July 28, 2025, to reveal topline results from the PIK3CA Wild-Type Cohort of... Full story

Yahoo Finance • 2 months ago

Top movers in Friday's after hours session

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] GAINERS TICKER CHANGE COMMENT MCVT [https://www.chartmill.com/stock/quote/MCVT/profile] 14.75%... Full story

Yahoo Finance • 2 months ago

Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer

MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the first patient has been dosed in VIKTORI... Full story